We then investigated the probability that a newly diagnosed CML patient responds to one or a combination of the BCR-ABL inhibitors imatinib, dasatinib, and nilotinib. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.